(Q34417576)

2 August 2017

1 reference

title

Antibody-directed, effector cell-mediated tumor destruction (English)

1 reference

2 August 2017

1 reference

Sondel PM

1

1 reference

2 August 2017

Hank JA

series ordinal

2

1 reference

2 August 2017

publication date

1 August 2001

1 reference

Hematology / Oncology Clinics of North America

2 August 2017

published in

1 reference

2 August 2017

volume

15

1 reference

2 August 2017

issue

4

1 reference

2 August 2017

page(s)

703-721

1 reference

T cell-mediated eradication of murine metastatic melanoma induced by targeted interleukin 2 therapy

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Assessment of the efficacy of purging by using gene marked autologous marrow transplantation for children with AML in first complete remission

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Clinical and immune responses in advanced melanoma patients immunized with an anti-idiotype antibody mimicking disialoganglioside GD2.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

A phase I/IB trial of murine monoclonal anti-GD2 antibody 14.G2a plus interleukin-2 in children with refractory neuroblastoma: a report of the Children's Cancer Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

High-level expression of chimeric antibodies using adapted cDNA variable region cassettes

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Antibody-targeted interleukin 2 stimulates T-cell killing of autologous tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Biological activity and in vivo clearance of antitumor antibody/cytokine fusion proteins

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

The CAMPATH-1 antigen (CDw52)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

A phase I study of human/mouse chimeric antiganglioside GD2 antibody ch14.18 in patients with neuroblastoma

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Rapid regression of chemotherapy refractory lymphocyte predominant Hodgkin's disease after administration of rituximab (anti CD 20 mono- clonal antibody) and interleukin-2.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Targeted interleukin-2 therapy for spontaneous neuroblastoma metastases to bone marrow

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Antiantiidiotypic Response and Clinical Course of the Disease in Patients with Malignant Melanoma Immunized with Mouse Antiidiotypic Monoclonal Antibody MK2-23

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Therapeutic potential of chimeric and murine anti-(epidermal growth factor receptor) antibodies in a metastasis model for human melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Phase I study of chimeric human/murine anti-ganglioside G(D2) monoclonal antibody (ch14.18) with granulocyte-macrophage colony-stimulating factor in children with neuroblastoma immediately after hematopoietic stem-cell transplantation: a Children's

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Targeted therapies for high-risk acute myeloid leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Recombinant antibody fusion proteins for cancer immunotherapy.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Randomised trial of monoclonal antibody for adjuvant therapy of resected Dukes' C colorectal carcinoma. German Cancer Aid 17-1A Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Tumor immunity in perforin-deficient mice: a role for CD95 (Fas/APO-1)

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Reengineered monoclonal antibodies step up to the plate in cancer studies

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Increased expression of the interleukin 2 (IL-2) receptor beta chain (p70) on CD56+ natural killer cells after in vivo IL-2 therapy: p70 expression does not alone predict the level of intermediate affinity IL-2 binding

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

Phase I trial of a human-mouse chimeric anti-disialoganglioside monoclonal antibody ch14.18 in patients with refractory neuroblastoma and osteosarcoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0889-8588%2805%2970243-4

7 January 2021

10.1016/S0889-8588(05)70243-4

Identifiers

DOI

1 reference

2 August 2017

1 reference